Financial reports
ARS
2023 FY
Annual report to shareholders
23 Apr 24
10-K
2023 FY
Annual report
15 Mar 24
NT 10-K
Notice of late annual filing
28 Feb 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
10-Q
2023 Q1
Quarterly report
4 May 23
ARS
2022 FY
Annual report to shareholders
1 May 23
10-K
2022 FY
Annual report
8 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
Current reports
8-K
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update
28 Feb 24
8-K
Departure of Directors or Certain Officers
16 Jan 24
8-K
Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates
8 Jan 24
8-K
Other Events
18 Dec 23
8-K
Results of Operations and Financial Condition
2 Nov 23
8-K/A
Financial Statements and Exhibits
2 Nov 23
8-K
Other Events
17 Oct 23
8-K
Other Events
13 Oct 23
8-K
Departure of Directors or Certain Officers
11 Sep 23
8-K
Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics
5 Sep 23
Registration and prospectus
S-8
Registration of securities for employees
15 Mar 24
S-8
Registration of securities for employees
2 Nov 23
424B5
Prospectus supplement for primary offering
2 Nov 23
S-3ASR
Automatic shelf registration
13 Oct 23
S-8
Registration of securities for employees
9 Mar 23
S-3ASR
Automatic shelf registration
9 Sep 22
424B5
Prospectus supplement for primary offering
10 Aug 22
424B5
Prospectus supplement for primary offering
9 Aug 22
S-3
Shelf registration
25 May 22
S-8
Registration of securities for employees
9 Mar 22
Proxies
DEFA14A
Additional proxy soliciting materials
23 Apr 24
DEF 14A
Definitive proxy
23 Apr 24
DEFA14A
Additional proxy soliciting materials
1 May 23
DEF 14A
Definitive proxy
1 May 23
DEFA14A
Additional proxy soliciting materials
22 Apr 22
DEF 14A
Definitive proxy
22 Apr 22
DEFA14A
Additional proxy soliciting materials
14 Apr 21
DEF 14A
Definitive proxy
14 Apr 21
DEFA14A
Additional proxy soliciting materials
29 Apr 20
DEF 14A
Definitive proxy
29 Apr 20
Other
EFFECT
Notice of effectiveness
10 Jun 22
CORRESP
Correspondence with SEC
6 Jun 22
UPLOAD
Letter from SEC
3 Jun 22
EFFECT
Notice of effectiveness
13 Aug 20
UPLOAD
Letter from SEC
7 Aug 20
EFFECT
Notice of effectiveness
9 Jan 20
CORRESP
Correspondence with SEC
6 Jan 20
CORRESP
Correspondence with SEC
6 Jan 20
UPLOAD
Letter from SEC
30 Dec 19
EFFECT
Notice of effectiveness
18 Jul 19
Ownership